Crinetics Pharmaceuticals, Inc. (CRNX)
Market Cap | 3.59B |
Revenue (ttm) | 1.97M |
Net Income (ttm) | -235.46M |
Shares Out | 78.86M |
EPS (ttm) | -3.76 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,234,438 |
Open | 46.09 |
Previous Close | 46.07 |
Day's Range | 45.19 - 47.18 |
52-Week Range | 15.76 - 53.70 |
Beta | 0.65 |
Analysts | Strong Buy |
Price Target | 63.75 (+39.99%) |
Earnings Date | Aug 6, 2024 |
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide ... [Read more]
Financial Performance
In 2023, CRNX's revenue was $4.01 million, a decrease of -15.28% compared to the previous year's $4.74 million. Losses were -$214.53 million, 30.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for CRNX stock is "Strong Buy." The 12-month stock price forecast is $63.75, which is an increase of 39.99% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/e/p/press11-2485612.jpg)
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives
![](https://cdn.snapi.dev/images/v1/i/w/press19-2472365.jpg)
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted n...
![](https://cdn.snapi.dev/images/v1/h/0/press12-2459534.jpg)
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine
![](https://cdn.snapi.dev/images/v1/o/j/press14-2459535.jpg)
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)
100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg)
![](https://cdn.snapi.dev/images/v1/g/g/press13-2454880.jpg)
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr....
![](https://cdn.snapi.dev/images/v1/p/4/press14-2443186.jpg)
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel ...
![](https://cdn.snapi.dev/images/v1/l/6/press1-2425145.jpg)
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non...
![](https://cdn.snapi.dev/images/v1/c/c/press8-2422518.jpg)
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant ( CRN 0 4894) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing's Syndrome Will be Presented at ENDO June ...
![](https://cdn.snapi.dev/images/v1/8/y/conf1-2407530.jpg)
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the ...
![](https://cdn.snapi.dev/images/v1/l/q/press13-2368094.jpg)
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted...
Under-the-radar biotech bets
Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.
![](https://cdn.snapi.dev/images/v1/b/i/biotech27-10-2330457.jpg)
Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study
Crinetics Pharmaceuticals said on Tuesday its experimental drug to treat a hormonal disorder met the main goal in a late-stage study.
![](https://cdn.snapi.dev/images/v1/j/j/press12-2330365.jpg)
Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p
![](https://cdn.snapi.dev/images/v1/a/q/press5-2320912.jpg)
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements
![](https://cdn.snapi.dev/images/v1/b/l/press2-2318613.jpg)
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted...
![](https://cdn.snapi.dev/images/v1/o/v/press5-2299501.jpg)
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024
![](https://cdn.snapi.dev/images/v1/2/d/press14-2298241.jpg)
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics” or the “Company”), a clinical-stage pharmaceutical company focused on the discovery, developmen...
![](https://cdn.snapi.dev/images/v1/m/6/conf3-2276658.jpg)
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, Februa...
![](https://cdn.snapi.dev/images/v1/k/u/press4-2272264.jpg)
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2024, the Compensation Committee of Crinetics' Board of Directors grant...
![](https://cdn.snapi.dev/images/v1/e/h/press13-2224833.jpg)
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2024, the Compensation Committee of Crinetics' Board of Directors grante...
![](https://cdn.snapi.dev/images/v1/7/z/press2-2200853.jpg)
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent...
![](https://cdn.snapi.dev/images/v1/1/h/press9-2191835.jpg)
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of nove...
![](https://cdn.snapi.dev/images/v1/z/y/conf11-2166004.jpg)
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI He...
![](https://cdn.snapi.dev/images/v1/d/l/press13-2153071.jpg)
Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of nove...
![](https://cdn.snapi.dev/images/v1/v/x/press4-2106785.jpg)
GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Craig Gordon, MD, Chief Executive Officer of GordonMD® Global Investments LP, announced today that his firm has jointly invested in a private placement financin...